|
Caplin Point Laboratories Ltd share price gained 0.80% to Rs 2520.95 after the company's net profit inched up 1.82% to Rs 182.35 crore, while revenue from operations slightly gained 3.19% to Rs 629.84 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 5.84%. It has marginally improved by 3.49% over last one week and ticked higher by 6.26% in last one month while the market capitalization of Caplin Point Laboratories Ltd has improved by 4.06% and 1.63% in the same period respectively.
Profit before tax (PBT) of Caplin Point Laboratories Ltd stood at Rs 232.83 crore in Q2 FY27, expanding by 15.84% year-on-year, and easing 3.38% quarter-on-quarter. EBITDA came in at Rs 190 crore, surging by 19.60% YoY and gaining 5.56% sequentially.
Total expenses posted a minor rise of 2.77% to Rs 430.11 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 106.15 crore, slightly declining by 0.85% YoY, while employee benefits expense was at Rs 57.59 crore, inching up 6.39% YoY.
For FY26, revenue from operations improved 12.89% to Rs 2187.19 crore, while net profit soared by 20.08% to Rs 649.73 crore, compared to previous FY. EBITDA surged by 55631% to Rs 645.31 crore, and PBT rose 18.62% to Rs 802.79 crore compared to previous FY.
The company's consolidated net cash flow from operating activities stood at Rs 523.23 crore in FY26, as against Rs 432.37 crore in FY25.
Caplin Point Laboratories Ltd jumped 29.37% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.37% during the same period.
|